<DOC>
	<DOCNO>NCT02500329</DOCNO>
	<brief_summary>This phase 4 , single center , randomize , open-labeled study . The primary objective study compare effect gemigliptin acarbose endothelial function . Subjects randomize gemigliptin acarbose group maintain intial treatment 4 week .</brief_summary>
	<brief_title>Effect Gemigliptin Acarbose Endothelial Function Type 2 DM Patients</brief_title>
	<detailed_description />
	<mesh_term>Acarbose</mesh_term>
	<criteria>age : 2080yrs patient type 2 diabetes ( duration diabetes &gt; =3 month ) HbA1c : &gt; 7.0 &lt; =9.0 % metformin monotherapy change medication recent 3 month . patient type 1 diabetes history medication include Î±glucosidase inhibitor , glinide , GLP1 analogue , DPP4 Inhibitors , insulin recent 3 month . history acute diabetic complication , acute coronary event , coronary bypass surgery/interventions recent 6 month . patient congestive heart failure ( NYHA II~IV ) clinically significant ventricular arrhythmia serum ALT AST &gt; 2.5 x upper normal range serum direct bilirubin &gt; 1.3 x upper normal range serum creatinine &gt; ( men ) 1.5 mg/dL , ( woman ) &gt; 1.4 mg/dL smoker pregnant woman , breastfeed woman medication acetylsalicylic acid vitamin K antagonist</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>July 2015</verification_date>
</DOC>